 Validating tumour and stromal immune features that correlate with optimal benefit from BCG and Mitomycin: a translational study of patients in the BCG+MM Trial

Redfern, Andrew (Investigator 01)

Internal Medicine

Status	Not started
Effective start/end date	1/08/26 → 31/08/27

Funding

Australian and New Zealand Urogenital and Prostate Cancer Trials Group: A$50,000.00